Screener
Vertex Pharmaceuticals VRTX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Vertex Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Vertex Pharmaceuticals’s 8-K, filed August 3, 2026. Open the filing →
- Filed
- Aug 3, 2026, 4:09 PM EDT
- Accession
- 0000875320-26-000256
FAQ
- What is Vertex Pharmaceuticals's return on equity?
- Vertex Pharmaceuticals (VRTX) reported return on equity of 23.5% in Q2 2026.
- What is the long-term trend for Vertex Pharmaceuticals's return on equity?
- Over 4 years (2020 to 2025), Vertex Pharmaceuticals's return on equity has grown at a -11.5% compound annual growth rate (CAGR), from 36.7% to 22.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Vertex Pharmaceuticals's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude